Abstract
In individuals with chronic kidney disease (CKD), Black and South Asian ethnic groups are twice as likely to have severe COVID-19 compared to White participants, whilst the most socially deprived groups are at a 50-60% increased risk of severe COVID-19.
This study is the first to highlight the association between ethnicity and socioeconomic deprivation and the risk of severe COVID-19 among those with CKD in the UK.
Interventions to reduce morbidity and mortality amongst these groups and policy and practice improvements are needed to address the broad disparity among CKD patients.
- COVID-19
- ethnicity
- health inequalities
- socioeconomic status
- chronic kidney disease
Competing Interest Statement
TJW, FZ, CJL, ACS, TY: None. KK: Director of the University of Leicester Centre for Ethnic Health Research, Trustee of the South Asian Health Foundation and Chair of the Ethnicity Subgroup of SAGE.
Clinical Trial
Data taken from UK Biobank.
Funding Statement
This work was supported by the Stoneygate Trust, NIHR Leicester Biomedical Research Centre, Leicester Real World Evidence Unit, University of Leicester, and NIHR Applied Research Collaboration (ARC) East Midlands. The study is registered as UK Biobank Application Number 52553. KK is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and the NIHR Leicester Biomedical Research Centre (BRC). TY is funded by a grant from the UKRI-DHSC COVID-19 Rapid Response Rolling Call (MR/V020536/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study uses UK Biobank data. Participants from the general population were recruited between March 2006 and December 2010. UK Biobank was approved by the North West Multi-Centre Research Ethics Committee (11/NW/0382). All participants provided informed consent. This work was conducted under application number 52553.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding This work was supported by the Stoneygate Trust, NIHR Leicester Biomedical Research Centre, Leicester Real World Evidence Unit, University of Leicester, and NIHR Applied Research Collaboration (ARC) East Midlands. The study is registered as UK Biobank Application Number 52553.
KK is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and the NIHR Leicester Biomedical Research Centre (BRC). TY is funded by a grant from the UKRI-DHSC COVID-19 Rapid Response Rolling Call (MR/V020536/1).
Data Availability
Data available through UK Biobank.
